BCR-ABL Quantitative MRD Monitor Test
Understanding the BCR-ABL Quantitative MRD Monitor Test
The BCR-ABL Quantitative MRD Monitor Test represents a breakthrough in leukemia management and monitoring. This sophisticated molecular diagnostic test detects and quantifies minimal residual disease (MRD) in patients with specific types of leukemia, particularly chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). MRD refers to the small number of cancer cells that remain in the body after treatment, which are undetectable by conventional methods but can lead to disease relapse if not properly monitored.
What Does This Test Measure?
The BCR-ABL Quantitative MRD Monitor Test specifically targets and measures the BCR-ABL fusion gene transcript levels in blood or bone marrow samples. This genetic abnormality results from a translocation between chromosomes 9 and 22, creating the Philadelphia chromosome, which is characteristic of CML and some cases of ALL. The test utilizes Real-Time Polymerase Chain Reaction (PCR) technology to provide highly sensitive and quantitative results, detecting as few as one leukemia cell among 100,000 normal cells.
- Quantifies BCR-ABL fusion gene transcript levels
- Detects minimal residual disease at molecular levels
- Monitors treatment response over time
- Provides early warning of potential relapse
- Assesses depth of molecular remission
Who Should Consider This Test?
This test is particularly important for patients diagnosed with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Individuals undergoing treatment with tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib should regularly monitor their MRD status. The test is also crucial for patients who have achieved hematological remission but require ongoing monitoring to ensure molecular remission.
Key Indications Include:
- Patients with newly diagnosed CML or Ph+ ALL
- Individuals undergoing TKI therapy
- Patients in hematological remission
- Those experiencing unexplained symptoms during treatment
- Patients being considered for treatment discontinuation
- Individuals with rising white blood cell counts
Benefits of the BCR-ABL Quantitative MRD Monitor Test
This advanced diagnostic test offers numerous benefits for both patients and healthcare providers. By providing precise molecular monitoring, it enables early intervention and personalized treatment adjustments. The ability to detect minimal residual disease before clinical symptoms appear significantly improves patient outcomes and quality of life.
Primary Benefits:
- Early Relapse Detection: Identifies molecular relapse months before clinical symptoms appear
- Treatment Optimization: Guides therapy adjustments based on molecular response
- Prognostic Information: Provides valuable insights into disease progression and treatment efficacy
- Treatment Discontinuation Guidance: Helps determine when TKI therapy can be safely stopped
- Peace of Mind: Regular monitoring reduces anxiety about disease recurrence
Understanding Your Test Results
Your BCR-ABL Quantitative MRD Monitor Test results will provide crucial information about your disease status and treatment response. The results are typically reported as the BCR-ABL/ABL ratio, which compares the level of BCR-ABL transcripts to normal ABL transcripts. This ratio helps determine your molecular response level and guides treatment decisions.
Result Interpretation Guidelines:
- Major Molecular Response (MMR): BCR-ABL/ABL ratio ≤ 0.1% indicates excellent treatment response
- Complete Molecular Response (CMR): Undetectable BCR-ABL transcripts suggest deep remission
- Rising Levels: Increasing BCR-ABL levels may indicate treatment resistance or impending relapse
- Stable Low Levels: Consistent low levels suggest good disease control
It’s essential to discuss your results with your hematologist or oncologist, who will interpret them in the context of your overall clinical picture and treatment history.
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $206 |
| Regular Price | $276 |
Sample Requirements and Turnaround Time
Sample Type: 5 mL (3 mL minimum) whole blood or bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.
Turnaround Time: Samples accepted Monday, Wednesday, Friday by 9 AM; Reports available Tuesday, Thursday, Saturday
Important Note: Duly filled MRD Requisition Form (Form 22) with historical data is mandatory for accurate interpretation.
Book Your Test Today
GGC DNA has branches across the United States, including major cities like New York, Los Angeles, Chicago, Houston, and Phoenix. Our state-of-the-art molecular diagnostics laboratories ensure accurate and reliable results for your BCR-ABL Quantitative MRD Monitor Test.
Take control of your leukemia management today. Call or WhatsApp us at +1(267) 388-9828 to schedule your test or speak with our genetic counseling team.
Early detection and regular monitoring are key to successful leukemia management. Trust GGC DNA for precise molecular diagnostics that can make a significant difference in your treatment journey and long-term health outcomes.
